Northland Securities initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Thursday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $28.00 target price on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the stock. Citigroup reaffirmed an add rating on shares of vTv Therapeutics in a report on Wednesday, November 8th. Canaccord Genuity set a $15.00 target price on shares of vTv Therapeutics and gave the company a buy rating in a report on Thursday, December 21st. Finally, Stifel Nicolaus reissued a buy rating and set a $12.00 price objective on shares of vTv Therapeutics in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $16.42.

Shares of vTv Therapeutics (VTVT) opened at $6.49 on Thursday. The firm has a market cap of $202.65 and a P/E ratio of -3.96. vTv Therapeutics has a 1-year low of $3.57 and a 1-year high of $8.40.

In related news, Director Paul G. Savas acquired 15,000 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were bought at an average price of $4.56 per share, with a total value of $68,400.00. Following the completion of the acquisition, the director now owns 81,781 shares in the company, valued at $372,921.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of the business’s stock in a transaction on Tuesday, December 26th. The shares were bought at an average cost of $4.03 per share, for a total transaction of $201,500.00. The disclosure for this purchase can be found here. 0.80% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Royce & Associates LP acquired a new stake in vTv Therapeutics during the fourth quarter worth approximately $1,352,000. Creative Planning acquired a new stake in vTv Therapeutics during the fourth quarter worth approximately $114,000. JPMorgan Chase & Co. acquired a new stake in vTv Therapeutics during the third quarter worth approximately $481,000. State Street Corp raised its holdings in vTv Therapeutics by 2.1% during the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in vTv Therapeutics by 62.7% during the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after purchasing an additional 101,850 shares in the last quarter. 10.52% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://theolympiareport.com/2018/02/11/northland-securities-begins-coverage-on-vtv-therapeutics-vtvt.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.